Hypofractionated intensity-modulated radiotherapy with simultaneous integrated boost after radical prostatectomy: Preliminary results of a phase II trial

Anticancer Research

Volumn 33, Issue 6, 2013, Pages 2785-2790

  Massaccesi, Mariangela ^a   Cilla, Savino ^b   Deodato, Francesco ^a   Digesú, Cinzia ^a   Macchia, Gabriella ^a   Caravatta, Luciana ^a   Ippolito, Edy ^a   Picardi, Vincenzo ^a   Ferro, Marica ^a   Mignogna, Samantha ^b   Mattiucci, Gian Carlo ^c   Valentini, Vincenzo ^c   Piermattei, Angelo ^b   Morganti, Alessio Giuseppe ^a,b,c  

^a CATHOLIC UNIVERSITY   (Italy)

^b Fondazione di Ricerca e Cura Giovanni Paolo II   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Hypofractionation; Phase II trial; Post operative radiotherapy; Prostate cancer; SIB IMRT

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GASTROINTESTINAL DISEASE; HUMAN; HYPOFRACTIONATED INTENSITY MODULATED RADIATION THERAPY; INTENSITY MODULATED RADIATION THERAPY; MALE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RADIATION DOSE FRACTIONATION; RADIATION INJURY; SIMULTANEOUS INTEGRATED BOOST INTENSITY MODULATED RADIATION THERAPY; UROGENITAL TRACT DISEASE; ADENOCARCINOMA; HYPOFRACTIONATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; POST-OPERATIVE RADIOTHERAPY; PROSTATE CANCER; PROSTATE TUMOR; SIB-IMRT;

HYPOFRACTIONATION; PHASE II TRIAL; POST-OPERATIVE RADIOTHERAPY; PROSTATE CANCER; SIB-IMRT;

ADENOCARCINOMA; AGED; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY, INTENSITY-MODULATED;

MLCS; MLOWN;

EID: 84881358941     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Marechal JM, Scalliet P, Haustermans K and Pierart M: European Organization for Research and Treatment of Cancer: Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 366: 572-578, 2005.
2. Thompson IM Jr., Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E and Crawford ED: Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296: 2329-2335, 2006.
3. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, Willich N, Semjonow A, Souchon R, Stockle M, Rube C, Weissbach L, Althaus P, Rebmann U, Kalble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W and Miller K: Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27: 2924-2930, 2009.
4. Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM and Crawford ED: Predominant treatment failure in postprostatectomy patients is local: Analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25: 2225-2229, 2007.
5. Cozzarini C, Montorsi F, Fiorino C, Alongi F, Bolognesi A, Da Pozzo LF, Guazzoni G, Freschi M, Roscigno M, Scattoni V, Rigatti P and Di Muzio N: Need for high radiation dose (> or =70 Gy) in early postoperative irradiation after radical prostatectomy: A single-institution analysis of 334 high-risk, node-negative patients. Int J Radiat Oncol Biol Phys 75: 966-974, 2009.
6. Bellavita R, Massetti M, Abraha I, Lupattelli M, Mearini L, Falcinelli L, Farneti A, Palumbo I, Porena M and Aristei C: Conformal postoperative radiotherapy in patients with positive resection margins and/or pT3-4 prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 84: e299-304, 2012.
7. Spiotto MT, Hancock SL and King CR: Radiotherapy after prostatectomy: Improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys 69: 54-61, 2007.
8. Digesu C, Cilla S, De Gaetano A, Massaccesi M, Macchia G, Ippolito E, Deodato F, Panunzi S, Iapalucci C, Mattiucci GC, D'Angelo E, Padula GD, Valentini V, Cellini N, Piermattei A and Morganti AG: Postoperative intensity modulated radiation therapy in high risk prostate cancer: A dosimetric comparison. Med Dosim 36: 231-239, 2011.
9. Alongi F, Fiorino C, Cozzarini C, Broggi S, Perna L, Cattaneo GM, Calandrino R and Di Muzio N: IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol 93: 207-212, 2009.
10. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD and Armour EP: Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52: 6-13, 2002.
11. Li XA, Wang JZ, Jursinic PA, Lawton CA and Wang D: Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 61: 1251-1257, 2005.
12. Ippolito E, Cellini N, Digesu C, Cilla S, Mantini G, Balducci M, Di Lallo A, Deodato F, Macchia G, Massaccesi M, Mattiucci GC, Tagliaferri L, Piermattei A, Cuscuna D and Morganti AG: Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: A dose-escalation trial. Urol Oncol 31: 87-92, 2013.
13. Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, Reuter V, Graefen M, Hammerer PG, Erbersdobler A, Huland H, Kupelian P, Klein E, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG, Scardino PT and Kattan MW: preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 170: 1798-1803, 2003
14. Roach M 3rd, Marquez C, Yuo HS, Narayan P, Coleman L, Nseyo UO, Navvab Z and Carroll PR: Predicting the risk of lymph node involvement using the pretreatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28: 33-37, 1993.
15. Barth PJ, Gerharz EW, Ramaswamy A and Riedmiller H: The influence of lymph node counts on the detection of pelvic lymph node metastasis in prostate cancer. Pathol Res Pract 195: 633-636, 1999.
16. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB and Thompson I: Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177: 540-545, 2007.
17. Poortmans P, Bossi A, Vandeputte K, Bosset M, Miralbell R, Maingon P, Boehmer D, Budiharto T, Symon Z, van den Bergh AC, Scrase C, Van Poppel H and Bolla M: Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol 84: 121-127, 2007.
18. Lengele B and Scalliet P: Anatomical bases for the radiological delineation of lymph node areas. Part III: Pelvis and lower limbs. Radiother Oncol 92: 22-33, 2009.
19. ICRU. International Commission on Radiation Units and Measurements: Prescribing, recording, and reporting photonbeam intensity-modulated radiation therapy (IMRT). ICRU Report 83. J ICRU 10: 1-106, 2010.
20. Deodato F, Cilla S, Massaccesi M, Macchia G, Ippolito E, Caravatta L, Picardi V, Romanella M, Di Falco C, Bartollino A, Valentini V, Cellini N, De Spirito M, Piermattei A and Morganti AG: Daily on-line set-up correction in 3D-conformal radiotherapy: Is it feasible? Tumori 98: 441-444, 2012.
21. Cox JD, Stetz JA and Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31: 1341-1346, 1995.
22. Williams SG, Taylor JM, Liu N, Tra Y, Duchesne GM, Kestin LL, Martinez A, Pratt GR and Sandler H: Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 68: 24-33, 2007.
23. Steel GG: Basic Clinical Radiobiology. London; Arnold, 2003.
24. Alongi F, Cozzarini C, Di Muzio N and Scorsetti M: Postoperative radiotherapy in prostate cancer: Acquired certainties and still open issues. A review of recent literature. Tumori 97: 1-8, 2012.